QAS.AI Inc. is structured around development and commercialization of software integrated with image guided surgical equipment to optimize neurovascular treatments. The firm's multidisciplinary team has expertise in biomedical engineering, neurosurgery and pathology. Described as providing solutions for real-time assistance during endovascular procedures, the firm's AI-driven software can be used during surgery to detect areas of inadequate blood flow in the brain and predict efficacy of aneurysm correction six months after embolization.